{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:11:57Z","timestamp":1790863917675,"version":"4.1.0"},"reference-count":28,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,3,18]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Long-term benzodiazepine use is common despite known risks. In the original Eliminating Medications Through Patient Ownership of End Results (EMPOWER) Study set in Canada, patient education led to increased rates of benzodiazepine cessation. We aimed to determine the effectiveness of implementing an adapted EMPOWER quality improvement (QI) initiative in a US-based healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We used a pre\u2013post design with a non-randomised control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A network of primary care clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients with \u226560 days\u2019 supply of benzodiazepines in 6 months and \u22651\u2009risk factor (\u226565 years of age, a concurrent high-risk medication prescribed or a diazepam equivalent daily dose \u226510) were eligible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>In March 2022, we engaged 22 primary care physicians (PCPs), and 308 of their patients were mailed an educational brochure, physician letter and flyer detailing benzodiazepine risks; the control group included 4 PCPs and 291 of their patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary measures<\/jats:title>\n                    <jats:p>The primary measure was benzodiazepine cessation by 9 months. We used logistic regression and a generalised estimating equations approach to control for clustering by PCP, adjusting for demographics, frailty, number of risk factors, and diagnoses of arthritis, depression, diabetes, falls, and pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients in the intervention and control groups were comparable across most covariates; however, a greater proportion of intervention patients had pain-related diagnoses and depression. By 9 months, 26% of intervention patients (81 of 308) had discontinued benzodiazepines, compared with 17% (49 of 291) of control patients. Intervention patients had 1.73 greater odds of benzodiazepine discontinuation compared with controls (95%\u2009CI: 1.09, 2.75, p=0.02). The unadjusted number needed to treat was 10.5 (95% CI: 6.30, 34.92) and the absolute risk reduction was 0.095 (95% CI: 0.03 to 0.16).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results from this non-randomised QI initiative indicate that patient education programmes using the EMPOWER brochures have the potential to promote cessation of benzodiazepines in primary care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-080109","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T13:52:57Z","timestamp":1712152377000},"page":"e080109","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Implementation of an intervention aimed at deprescribing benzodiazepines in a large US healthcare system using patient education materials: a pre\/post-observational study with a control group"],"prefix":"10.1136","volume":"14","author":[{"given":"Tammy M","family":"Le","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Campbell","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Care Foundation, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Andraos","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Care Foundation, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Ahlmark","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Care Foundation, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha","family":"Hoang","sequence":"additional","affiliation":[{"name":"Enterprise Data Intelligence, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Isserman","sequence":"additional","affiliation":[{"name":"Enterprise Data Intelligence, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L","family":"Goldzweig","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Care Foundation, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3381-4938","authenticated-orcid":false,"given":"Allison M","family":"Mays","sequence":"additional","affiliation":[{"name":"Section of Geriatrics, Division of General Internal Medicine, Medicine, Cedars-Sinai Medical Center, Beverly Hills, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Bradley","sequence":"additional","affiliation":[{"name":"UNC Rex Healthcare, Raleigh, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8157-7586","authenticated-orcid":false,"given":"Michelle S","family":"Keller","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA"},{"name":"Health Policy and Management, Jonathan and Karin Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"2025121223413750000_14.4.e080109.1","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13040059"},{"key":"2025121223413750000_14.4.e080109.2","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","article-title":"Benzodiazepine use in older adults: dangers, management, and alternative therapies","volume":"91","author":"Markota","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2025121223413750000_14.4.e080109.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174730","article-title":"Z-drugs and the risk of hip fracture: a systematic review and meta-analysis","volume":"12","author":"Donnelly","year":"2017","journal-title":"PLoS One"},{"key":"2025121223413750000_14.4.e080109.4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.2020.22106","article-title":"Balancing the risks and benefits of benzodiazepines","volume":"325","author":"Hirschtritt","year":"2021","journal-title":"JAMA"},{"key":"2025121223413750000_14.4.e080109.5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency Department visits and overdose deaths from combined use of opioids and benzodiazepines","volume":"49","author":"Jones","year":"2015","journal-title":"Am J Prev Med"},{"key":"2025121223413750000_14.4.e080109.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2003.12.007"},{"key":"2025121223413750000_14.4.e080109.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-019-6933-8","article-title":"Prevalence of prescribed benzodiazepine long-term use in the French general population according to Sociodemographic and clinical factors: findings from the CONSTANCES cohort","volume":"19","author":"Airagnes","year":"2019","journal-title":"BMC Public Health"},{"key":"2025121223413750000_14.4.e080109.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.2000.tb00715.x"},{"key":"2025121223413750000_14.4.e080109.9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19029","article-title":"Incidence of and characteristics associated with long-term benzodiazepine use in Finland","volume":"3","author":"Taipale","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025121223413750000_14.4.e080109.10","unstructured":"OECD . Trends in benzodiazepine use in adults aged 65 and over: chronic and long-acting use, 2009, 2019 (or nearest years) and 2020. OECD; 2021. Available: https:\/\/www.oecd-ilibrary.org\/social-issues-migration-health\/trends-in-benzodiazepine-use-in-adults-aged-65-and-over-chronic-and-long-acting-use-2009-2019-or-nearest-years-and-2020_e7c5b69a-en"},{"key":"2025121223413750000_14.4.e080109.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025121223413750000_14.4.e080109.12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40266-018-0544-4","article-title":"Deprescribing benzodiazepines in older patients: impact of interventions targeting physicians, pharmacists, and patients","volume":"35","author":"Ng","year":"2018","journal-title":"Drugs Aging"},{"key":"2025121223413750000_14.4.e080109.13","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-015-0019-8","article-title":"Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a Scoping review","volume":"16","author":"Pollmann","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"key":"2025121223413750000_14.4.e080109.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2257-8"},{"key":"2025121223413750000_14.4.e080109.15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamainternmed.2014.949","article-title":"Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education the EMPOWER cluster randomized trial","volume":"174","author":"Tannenbaum","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2025121223413750000_14.4.e080109.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015959","article-title":"A realist evaluation of patients\u2019 decisions to Deprescribe in the EMPOWER trial","volume":"7","author":"Martin","year":"2017","journal-title":"BMJ Open"},{"key":"2025121223413750000_14.4.e080109.17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.9740\/mhc.2018.05.100","article-title":"Effectiveness of a direct-to-consumer written health education program in the reduction of benzodiazepine and sedative-hypnotic use in an elderly population at a single veterans affairs medical center","volume":"8","author":"Erwin","year":"2018","journal-title":"Ment Health Clin"},{"key":"2025121223413750000_14.4.e080109.18","first-page":"1","article-title":"Pilot RCT testing A mailing about sleeping pills and cognitive behavioral therapy for insomnia: impact on benzodiazepines and Z-drugs","volume":"2022","author":"Mak","year":"2022","journal-title":"Clin Gerontol"},{"key":"2025121223413750000_14.4.e080109.19","unstructured":"Sparks A , Cohen A . Benzodiazepine and Z-Drug Safety Guideline. Kaiser Permanente, 2019."},{"key":"2025121223413750000_14.4.e080109.20","first-page":"1771","article-title":"Frailty screening using the electronic health record within a Medicare accountable care organization","volume":"74","author":"Pajewski","year":"2019","journal-title":"The Journals of Gerontology"},{"key":"2025121223413750000_14.4.e080109.21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1536867X1201200209","article-title":"Using the margins command to estimate and interpret adjusted predictions and marginal effects","volume":"12","author":"Williams","year":"2012","journal-title":"The Stata Journal"},{"key":"2025121223413750000_14.4.e080109.22","unstructured":"Froud R . BCII: Stata Module to to Estimate the Number Needed to Treat (NNT) and Confidence Intervals for Patients Improving, or \u2018Benefiting\u2019 (Either Improvements Gained or Deteriorations Prevented), in a Randomised Controlled Trial. Boston College Department of Economics: Statistical Software Components, 2009."},{"key":"2025121223413750000_14.4.e080109.23","first-page":"36","article-title":"Reducing benzodiazepine prescribing in older veterans: A direct-to-consumer educational brochure","volume":"35","author":"Mendes","year":"2018","journal-title":"Fed Pract"},{"key":"2025121223413750000_14.4.e080109.24","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/jgs.15300","article-title":"Empowering hospitalized older adults to Deprescribe sedative Hypnotics: A pilot study","volume":"66","author":"Wilson","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"2025121223413750000_14.4.e080109.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.16131"},{"key":"2025121223413750000_14.4.e080109.26","doi-asserted-by":"crossref","DOI":"10.1177\/2042098618816562","article-title":"The impact of in hospital patient-education intervention on older people\u2019s attitudes and intention to have their benzodiazepines Deprescribed: a feasibility study","volume":"10","author":"Gnjidic","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"2025121223413750000_14.4.e080109.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2018-000539","article-title":"Deprescribing benzodiazepines among hospitalised older adults: quality improvement initiative","volume":"8","author":"Carr","year":"2019","journal-title":"BMJ Open Qual"},{"key":"2025121223413750000_14.4.e080109.28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075828","article-title":"Impact of a Deprescribing tool on the use of sedative Hypnotics among older patients: study protocol for a cluster randomised controlled trial in Swiss primary care (the HYPE trial","volume":"13","author":"Weiss","year":"2023","journal-title":"BMJ Open"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-080109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:41:43Z","timestamp":1765611703000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-080109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,3]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bmjopen-2023-080109"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-080109","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}